NCT02691702 - Multiple Dose Study Of BIIB118 (PF-05251749) In Healthy Volunteers | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

March 28, 2016

Primary Completion Date

January 12, 2017

Study Completion Date

January 12, 2017

Conditions

Healthy Adult SubjectsHealthy Elderly Subjects

Interventions

DRUG

BIIB118

Multiple ascending doses of BIIB118 (50 mg, 150 mg, 450 mg and 900 mg) as extemporaneously prepared solution/suspension administered once daily over 2 weeks

DRUG

Melatonin

Positive control used to assess the validity of DLMO as pharmacodynamic endpoint.

Trial Locations (2)

33143

QPS-MRA, LLC (Miami Research Associates), South Miami

Qps-Mra, Llc, South Miami